Takeda Pharmaceutical (TAK) Stock Forecast & Price Target
Score
Takeda Pharmaceutical Company Limited analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
3 analysts cover TAK.
Takeda Pharmaceutical Company Limited EPS and revenue estimates
Published annual figures for TAK on this page are 2026 EPS $71.80, 2027 EPS $68.00. Coverage under three analysts is omitted.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $71.80 | $4.62T |
| 2027 | $68.00 | $4.71T |
Is Takeda Pharmaceutical Company Limited a buy or sell?
Of the 3 analysts covering Takeda Pharmaceutical Company Limited, 3 rate it a buy (0 strong buy and 3 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The TAK consensus label is Buy, beside 3 buy-side ratings and 0 sell-side ratings.
The TAK rating block is 3 published views with a Buy label. It does not tell you whether to buy or sell.
Reading the Takeda Pharmaceutical Company Limited forecast
The TAK rating mix is lopsided rather than split: 3 of 3 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
the Takeda Pharmaceutical Company Limited has a falling EPS path, $71.80 for 2026 and $68.00 for 2027.
With 3 firms in the TAK target set, the average is a small sample.
Takeda Pharmaceutical Company Limited forecast questions
What is the TAK price target?
No published price target is on file for TAK.
Is Takeda Pharmaceutical Company Limited a buy or sell?
Of the 3 analysts covering Takeda Pharmaceutical Company Limited, 3 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, leaving TAK at 3 buy ratings, 0 holds, and 0 sells.
What is the EPS estimate for Takeda Pharmaceutical Company Limited?
Analyst EPS estimates for Takeda Pharmaceutical Company Limited: 2026 $71.80, 2027 $68.00.
What is the revenue estimate for Takeda Pharmaceutical Company Limited?
Analyst revenue estimates for Takeda Pharmaceutical Company Limited: 2026 $4.62T, 2027 $4.71T.
How many analysts cover TAK?
3 analysts cover TAK. Their consensus on TAK is Buy, across those 3.